Beets J L, Kirby P J, Bray M A
Int J Immunopharmacol. 1979;1(1):29-34. doi: 10.1016/0192-0561(79)90027-4.
Horse anti-human lymphocyte globulin (HALG) is now widely clinically, but the variable immunosuppressive potency of different preparations of HALG has necessitated development of an accurate, reproducible in vitro assay of HALG potency. Currently available tests have several disadvantages, as well as showing little correlation with in vivo activity of the preparations tested. Incorporation of tritiated thymidine into lymphocytes, stimulated with mitogen (PHA) or antigen (PPD) and the inhibition of this process by HALG is described. ID50S and potency ratios have been determined for four HALG preparations. The ID50S obtained with these preparations were reproducible and the potency ratios obtained using 3 + 3 parallel line bioassay were similarly reproducible, a change in rank order being observed only once in ten assays. These in vitro results correlate with in vivo skin graft data. It is suggested that this technique could be used for evaluation of HALG preparations on peripheral blood from potential recipients.
马抗人淋巴细胞球蛋白（HALG）目前在临床上广泛应用，但不同制剂的HALG免疫抑制效力存在差异，因此需要开发一种准确、可重复的体外HALG效力测定方法。目前可用的检测方法存在几个缺点，并且与所测试制剂的体内活性相关性很小。本文描述了用氚标记的胸腺嘧啶核苷掺入经丝裂原（PHA）或抗原（PPD）刺激的淋巴细胞中，以及HALG对该过程的抑制作用。已测定了四种HALG制剂的半数抑制剂量（ID50）和效价比。用这些制剂获得的ID50具有可重复性，使用3 + 3平行线生物测定法获得的效价比同样具有可重复性，在十次测定中仅观察到一次排名顺序的变化。这些体外结果与体内皮肤移植数据相关。建议该技术可用于评估潜在受者外周血中HALG制剂的情况。
